NOXXON provides update on clinical trial recruitment and corporate operations during COVID-19 pandemic
(WorldNews Netherlands)

NOXXON PROVIDES UPDATE ON CLINICAL TRIAL RECRUITMENT AND CORPORATE OPERATIONS DURING COVID-19 PANDEMIC Berlin, Germany, March 31, 2020, 06.00 p.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), provided today a corporate update on its measures in response to the potential impact of COVID-19on business operations and its ongoing brain cancer clinical trial. As requested by the European Medicines Agency (EMA) in its guidance from March 20, 20201, NOXXON has critically assessed the risks and benefits of therapy continuation and inclusion of new trial participants in its...